Yesterday, the FDA issued a safety alert for Bard Recovery and Bard G2 filters, inferior vena cava (IVC) filters, manufactured by C.R. Bard. These filters are small devices that are implanted in to the inferior vena cava, the main blood vessel that returns blood from the lower half of the body, to prevent pulmonary embolism. The filters prevent blood clots from reaching the lungs where they would become fatal. Over the last five years, there have been 921 adverse event reports involving IVC filters - 328 cases where the device migrated in the body, 146 cases involving a detachment of a device component, 70 cases involving perforation, and 56 cases where the filter fractured. According to the FDA, many of these events may be related to a retrievable filter remaining in the body for long periods of time, beyond the time when the risk of a blood clot or pulmonary embolism has subsided.
Continue reading "FDA Warns of Major Problems for C.R. Bard’s Blood Clot IVC Filters " »